Page 1 | Search Results | Blood Neoplasia | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study

Mrinal M. Patnaik, Haris Ali, Eunice S. Wang, Abdulraheem Yacoub, James M. Foran, Vikas Gupta, Gary J. Schiller, Don Ambrose Stevens, Moshe Talpaz, Sarah Wall, Terra L. Lasho, Abhishek A. Mangaonkar, Talha Badar, Ross Lindsay, Antonio Galleu, Ira Gupta, Naveen Pemmaraju, Guillermo Garcia-Manero

Blood Neoplasia (2025) 2 (4): 100115.

https://doi.org/10.1016/j.bneo.2025.100115

Published: 2025

Includes: Supplemental data

Journal Articles

Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma

Tadeusz Kubicki, Benjamin A. Derman, Jennifer H. Cooperrider, Anna Puła, David Barnidge, Dominik Dytfeld, Ken Jiang, Andrzej J. Jakubowiak

Blood Neoplasia (2025) 2 (4): 100124.

https://doi.org/10.1016/j.bneo.2025.100124

Published: 2025

Includes: Supplemental data

Journal Articles

A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia

Blood Neoplasia (2025) 2 (4): 100126.

https://doi.org/10.1016/j.bneo.2025.100126

Published: 2025

Includes: Supplemental data

Journal Articles

Three-year follow-up of low-dose, early-start gilteritinib maintenance in posttransplant patients with R/R FLT3 mut AML

Toshiki Terao, Ken-ichi Matsuoka, Takumi Kondo, Yoshinobu Maeda

Blood Neoplasia (2025) 2 (4): 100141.

https://doi.org/10.1016/j.bneo.2025.100141

Published: 2025

Journal Articles

Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia

Blood Neoplasia (2025) 2 (3): 100110.

https://doi.org/10.1016/j.bneo.2025.100110

Published: 2025

Includes: Supplemental data

Journal Articles

Gut Faecalibacterium abundance in patients with plasma cell disorders is associated with survival after autologous HSCT

Erin A. Dean, Arkaprava Roy, Rick Y. Lin, Raad Z. Gharaibeh, Derek M. Li, Josee Gauthier, Christian Jobin, John R. Wingard

Blood Neoplasia (2025) 2 (3): 100114.

https://doi.org/10.1016/j.bneo.2025.100114

Published: 2025

Includes: Supplemental data

Journal Articles

Checkpoint immunotherapy is associated with preferential activation of tumor antigen–specific CD4 + T cells in MDS

Elizabeth A. Griffiths, Pragya Srivastava, Eduardo Cortes Gomez, Junko Matsuzaki, Kunle Odunsi, Laura W. Dillon, Devdeep Mukherjee, Christopher S. Hourigan, Jacqueline Peng, Shovik Bandyopadhyay, Kai Tan, Kristopher M. Attwood, Joseph B. Kuechle, Prashant K. Singh, Jianmin Wang, Michael J. Nemeth

Blood Neoplasia (2025) 2 (3): 100106.

https://doi.org/10.1016/j.bneo.2025.100106

Published: 2025

Includes: Supplemental data

Journal Articles

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia

Yesid Alvarado-Valero, Rachel J. Cook, Shira N. Dinner, Michael Keng, Kebede H. Begna, Nathalie Javidi-Sharifi, Sameem Abedin, Monzr M. Al Malki, Vijaya Raj Bhatt, Prabhu Rajagopalan, Min Tang, Sandra E. Wiley, Richard G. Ghalie, Matthew S. Davids

Blood Neoplasia (2025) 2 (3): 100108.

https://doi.org/10.1016/j.bneo.2025.100108

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes of myeloablative allogeneic hematopoietic cell transplantation with omidubicel vs alternative donor sources

Chenyu Lin, Smitha Sivaraman, Gautam Sajeev, Yan Song, Chunyi Xu, Chujun He, James E. Signorovitch, Heayoung Shin, Xiao-Ying Tang, Mei-Jie Zhang, Linda J. Burns, Ronit Simantov, Mitchell E. Horwitz

Blood Neoplasia (2025) 2 (3): 100104.

https://doi.org/10.1016/j.bneo.2025.100104

Published: 2025

Includes: Supplemental data

Journal Articles

Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis

Aaron S. Rosenberg, Emanual Maverakis, Caitlin Costello, Elizabeth A. Brem, Matthew Joseph Wieduwilt, Guillaume Luxardi, Paul Kaesberg, Keon Abedi, Samantha Herbert, Joseph Tuscano

Blood Neoplasia (2025) 2 (3): 100067.

https://doi.org/10.1016/j.bneo.2025.100067

Published: 2025

Includes: Supplemental data

Journal Articles

Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis

Blood Neoplasia (2025) 2 (2): 100092.

https://doi.org/10.1016/j.bneo.2025.100092

Published: 2025

Includes: Supplemental data

Journal Articles

Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN

Naveen Pemmaraju, Luan Hai Phan, Geoffrey Fell, Marlise R. Luskin, Mahesh Swaminathan, Sherry Pierce, Courtney DiNardo, Abhishek Maiti, Marina Konopleva, Andrew A. Lane

Blood Neoplasia (2025) 2 (2): 100086.

https://doi.org/10.1016/j.bneo.2025.100086

Published: 2025

Journal Articles

A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML

Patricia L. Kropf, Woonbok Chung, Raji Shameem, Lianchun Xiao, Curt Balch, Xuelin Huang, Jean-Pierre J. Issa

Blood Neoplasia (2025) 2 (2): 100071.

https://doi.org/10.1016/j.bneo.2025.100071

Published: 2025

Includes: Supplemental data

Journal Articles

Adult leukemia in Florida 2010-2019: diverse, aging population as an indicator for the United States

Ming S. Lee, Rebecca E. Kaiser, Christopher D. Armstrong, David B. Dukenik, Nancy S. Elliott, Raymond R. Balise, Justin M. Watts, Mikkael A. Sekeres, Erin N. Kobetz, Justin Taylor

Blood Neoplasia (2025) 2 (2): 100078.

https://doi.org/10.1016/j.bneo.2025.100078

Published: 2025

Journal Articles

Prognostic impact of RDI of vincristine in patients with DLBCL receiving R-CHOP: a supplementary analysis of JCOG0601

Takahiro Nakashima, Tomotaka Suzuki, Ryunosuke Machida, Kazuyuki Shimada, Tsutomu Kobayashi, Dai Maruyama, Wataru Munakata, Shinsuke Iida, Ken Ohmachi, Tomohiro Kinoshita, Kiyoshi Ando, Hirokazu Nagai

Blood Neoplasia (2025) 2 (2): 100077.

https://doi.org/10.1016/j.bneo.2025.100077

Published: 2025

Includes: Supplemental data

Journal Articles

Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myeloma

Blood Neoplasia (2025) 2 (1): 100051.

https://doi.org/10.1016/j.bneo.2024.100051

Published: 2025

Includes: Supplemental data

Journal Articles

A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies

Max J. Gordon, Sigrid Dubois, Milos D. Miljkovic, Samuel Ng, Bonita Bryant, Rahul Lakhotia, Christopher Melani, Stefania Pittaluga, Kevin Conlon, Thomas Waldmann, Louis M. Staudt, Wyndham H. Wilson, Mark Roschewski

Blood Neoplasia (2024) 2 (1): 100054.

https://doi.org/10.1016/j.bneo.2024.100054

Published: 2024

Journal Articles

JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study

Yu Uemura, Masahide Yamamoto, Masataka Ishimura, Hirokazu Kanegane, Akihisa Sawada, Akihiro Hirakawa, Ken-Ichi Imadome, Mayumi Yoshimori, Masashi Nagata, Kouhei Yamamoto, Norio Shimizu, Ryuji Koike, Ayako Arai

Blood Neoplasia (2024) 2 (1): 100053.

https://doi.org/10.1016/j.bneo.2024.100053

Published: 2024

Includes: Supplemental data

Journal Articles

Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response

Naveen Pemmaraju, Tim C.P. Somervaille, Francesca Palandri, Claire Harrison, Rami S. Komrokji, Andrew Perkins, Rosa M. Ayala Diaz, David Lavie, Akihiro Tomita, Yang Feng, Qin Qin, Jason Harb, Akshanth R. Polepally, Jalaja Potluri, Jacqueline S. Garcia

Blood Neoplasia (2024) 2 (1): 100056.

https://doi.org/10.1016/j.bneo.2024.100056

Published: 2024

Includes: Supplemental data

Journal Articles

Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma

Amrita Y. Krishnan, Krina K. Patel, Meera Mohan, Sundar Jagannath, Ruben Niesvizky, Rebecca W. Silbermann, Ziji Yu, Tao Long, Scott R. P. McDonnell, Deborah Berg, Keith E. Stockerl-Goldstein

Blood Neoplasia (2024) 1 (4): 100043.

https://doi.org/10.1016/j.bneo.2024.100043

Published: 2024

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study

Minimal residual disease measurement in blood by mass spectrometry identifies long-term responders in multiple myeloma

A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia

Three-year follow-up of low-dose, early-start gilteritinib maintenance in posttransplant patients with R/R FLT3 mut AML

Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia

Gut Faecalibacterium abundance in patients with plasma cell disorders is associated with survival after autologous HSCT

Checkpoint immunotherapy is associated with preferential activation of tumor antigen–specific CD4 + T cells in MDS

The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia

Outcomes of myeloablative allogeneic hematopoietic cell transplantation with omidubicel vs alternative donor sources

Clarithromycin, ixazomib, pomalidomide, dexamethasone for relapsed/refractory myeloma: survival and correlative analysis

Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis

Prospective clinical trials of venetoclax and hypomethylating agents for relapsed BPDCN

A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML

Adult leukemia in Florida 2010-2019: diverse, aging population as an indicator for the United States

Prognostic impact of RDI of vincristine in patients with DLBCL receiving R-CHOP: a supplementary analysis of JCOG0601

Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR T-cell manufacturing failure in myeloma

A phase 1 study of interleukin-15 in combination with mogamulizumab in relapsed and refractory T-cell malignancies

JAK1/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study

Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response

Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only